surufatinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Neuroendocrine Tumors

Pending FDA approval for pancreatic and nonpancreatic advanced neuroendocrine tumors (NET)

Next:

Pharmacology

Mechanism of Action

Angio-immuno kinase inhibitor that selectively inhibits tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR)

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.